Immunome Reports Increased Q1 Net Loss Amidst Key Pipeline Advancements and Varegacestat NDA Submission

summarizeSummary

Immunome Inc. reported an increased net loss of $53.8 million for Q1 2026, with cash and equivalents decreasing to $582.7 million. However, the company achieved a significant regulatory milestone by submitting a New Drug Application for varegacestat and advanced several other oncology candidates.

check_boxKey Events

• Increased Net Loss

  Immunome reported a net loss of $53.8 million for the three months ended March 31, 2026, an increase from $41.6 million in the same period last year.

• Cash Position and Runway

  Cash and cash equivalents decreased to $582.7 million as of March 31, 2026, from $653.5 million at December 31, 2025. The company projects its existing cash will fund operations for at least 12 months.

• Varegacestat NDA Submission

  The company submitted a New Drug Application (NDA) for varegacestat to the FDA in April 2026, following positive Phase 3 RINGSIDE trial results. A Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) is planned by the end of 2026.

• Pipeline Progression

  Immunome is advancing multiple oncology candidates, including IM-1021 (Phase 1 ongoing with objective responses), IM-3050 (Phase 1 initiated in March 2026), and IM-1617 (IND clearance in April 2026, Phase 1 planned for Q2 2026).

auto_awesomeAnalysis

Immunome Inc. reported a significant increase in its net loss for the first quarter of 2026, reflecting ongoing high research and development costs typical for a clinical-stage biotechnology company. Despite the increased cash burn, the company maintains a cash runway of at least 12 months. Critically, Immunome achieved a major regulatory milestone by submitting a New Drug Application for varegacestat to the FDA, following positive Phase 3 results. This moves their lead candidate closer to potential commercialization. The continued progression of other oncology candidates through early-stage clinical trials and IND clearances also highlights a robust development pipeline, balancing the negative financial performance with strong operational execution.